Senseonics Holdings, Inc. (NYSE American: SENS) ("Senseonics" or the "Company"), a medical technology company focused on the ...
Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for ...
Senseonics’ Eversense 365 is approved in the US as an integrated continuous glucose monitoring (iCGM) system for people with Type 1 and Type 2 diabetes aged 18 and older Commercial launch by ...
Ascensia Diabetes Care announced today that it launched the Eversense 365 CGM system from Senseonics (NYSE:SENS) ...
Approved by the U.S. Food and Drug Administration last month, Eversense 365 is an implantable CGM system that requires only one calibration per week after the initial 14 days. The launch of this ...
Ascensia Diabetes Care, a global diabetes care company, announces that it is launching the Eversense ® 365 continuous glucose monitoring (CGM) system, the world’s only One Year CGM, to people ...